GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2011

Nuron Chooses the Merck BioManufacturing Network for Phase III MS Candidate

  • Nuron Biotech selected the Merck BioManufacturing Network to produce large-scale GMP supplies of NU100 for an upcoming Phase III multiple sclerosis trial. Merck will also undertake process validation leading to long-term commercial operations.

    The manufacturing process will use a large-scale pressure refold technology, PreEMT™. It was licensed from BaroFold last May and has been installed at Merck’s Billingham, U.K. site.

    NU100 is a recombinant human interferon beta compound, which Nuron Biotech plans to take into late-stage trials later this year. Nuron says NU100 differs from other interferon-beta products because of PreEMT’s high-pressure protein disaggregation and refolding capabilities. The technology resulted in an interferon beta-1b product free of human serum albumin and essentially free of aggregates.

    The manufacturing agreement comes almost two weeks after Nuron announced an agreement with Catalent Pharma Solutions for the formulation and supply of NU100. Nuron, which initiated operations less than a year ago, has established late-stage product programs in three distinct disease areas: central nervous system diseases, wound healing, and vaccines.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?